<International Circulation>: The DECODE study sponsored by you found that the higher  postprandial blood glucose， the greater the risk of cardiovascular disease. Subsequent STOP-NIDDM study showed that acarbose could bring cardiovascular benefits to patients in pre-diabetes. To further explore the cardiovascular benefits of acarbose in patients with cardiovascular disease and abnormal glucose metabolism， the researchers signed ACE study. How do you think about the effect of acarbose on postprandial blood glucose and cardiovascular risk factors? Would you like to look ahead the findings of ACE study?
    Prof. Tuomilehto: Acarbose， was developed specifically to lower post-prandial glucose elevations in blood sugar after a meal. And so acarbose is very helpful for patients with postprandial hyperglycemia.  Most patients with glucose abnormalities have post-prandial glucose episodes.  At the same time it has been shown in studies that acarbose can be helpful in hypertensive patients as well as in weight control. In summary acarbose seems to be very helpful in treating patients with glucose abnormalities and cardiovascular disease.